- Home
- SDGR vs SNDX Comparison
SDGR vs SNDX Comparison
Compare SDGR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDGR
- SNDX
- Stock Information
- Founded
- SDGR 1990
- SNDX 2005
- Country
- SDGR United States
- SNDX United States
- Employees
- SDGR N/A
- SNDX N/A
- Industry
- SDGR Biotechnology: Pharmaceutical Preparations
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- SDGR Health Care
- SNDX Health Care
- Exchange
- SDGR Nasdaq
- SNDX Nasdaq
- Market Cap
- SDGR 1.4B
- SNDX 1.3B
- IPO Year
- SDGR 2020
- SNDX 2016
- Fundamental
- Price
- SDGR $20.87
- SNDX $13.61
- Analyst Decision
- SDGR Buy
- SNDX Strong Buy
- Analyst Count
- SDGR 8
- SNDX 11
- Target Price
- SDGR $26.75
- SNDX $38.55
- AVG Volume (30 Days)
- SDGR 1.3M
- SNDX 3.4M
- Earning Date
- SDGR 11-05-2025
- SNDX 11-03-2025
- Dividend Yield
- SDGR N/A
- SNDX N/A
- EPS Growth
- SDGR N/A
- SNDX N/A
- EPS
- SDGR N/A
- SNDX N/A
- Revenue
- SDGR $237,917,000.00
- SNDX $77,933,000.00
- Revenue This Year
- SDGR $22.73
- SNDX $629.90
- Revenue Next Year
- SDGR $19.85
- SNDX $114.74
- P/E Ratio
- SDGR N/A
- SNDX N/A
- Revenue Growth
- SDGR 18.59
- SNDX 2126.66
- 52 Week Low
- SDGR $16.60
- SNDX $8.58
- 52 Week High
- SDGR $28.47
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- SDGR 50.88
- SNDX 39.26
- Support Level
- SDGR $19.99
- SNDX $13.00
- Resistance Level
- SDGR $23.02
- SNDX $15.79
- Average True Range (ATR)
- SDGR 1.12
- SNDX 1.04
- MACD
- SDGR 0.03
- SNDX -0.23
- Stochastic Oscillator
- SDGR 47.94
- SNDX 18.60
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.